羟氯喹治疗自身免疫性疾病血药浓度影响因素分析

doi:10.12092/j.issn.1009-2501.2018.12.007

中国临床药理学与治疗学 ›› 2018, Vol. 23 ›› Issue (12): 1359-1363.doi: 10.12092/j.issn.1009-2501.2018.12.007

羟氯喹治疗自身免疫性疾病血药浓度影响因素分析

刘婷婷¹，余威²，杨春兰¹，帅宗文³，高贝贝¹，夏泉¹

¹安徽医科大学第一附属医院药剂科，国家中医药管理局中药化学三级实验室，合肥 230022，安徽；²安徽医科大学药学院，合肥 230032，安徽；³安徽医科大学第一附属医院风湿免疫科，合肥 230022，安徽

收稿日期:2018-09-16 修回日期:2018-10-19 出版日期:2018-12-26 发布日期:2018-12-27
通讯作者: 夏泉，男，博士，主任药师，副教授，硕士生导师，研究方向：治疗药物监测(TDM)技术的临床应用。 Tel: 0551-62922154 E-mail:xiaquan2010@163.com
作者简介:刘婷婷，女，博士，药师，副教授，研究方向：抗炎免疫药理学。 Tel: 15715695384 E-mail:908810474@qq.com
基金资助:
安徽省公益性技术应用研究联动计划项目(1604f0804028)；安徽医科大学第一附属医院2017年度新技术新项目

Blood concentration monitoring of hydroxychloroquine in patients with autoimmune diseases

LIU Tingting ¹, YU Wei ², YANG Chunlan ¹, SHUAI Zongwen ³, GAO Beibei ¹, XIA Quan ¹

¹Departmentof Pharmacy, the First Affiliated Hospital of Anhui Medical University, the Grade 3 Pharmaceutical Chemistry Laboratory of State Administration of Traditional Chinese Medicine, Hefei 230022, Anhui, China; ² School of Pharmacy, Anhui Medical University, Hefei 230032, Anhui, China; ³Department of Rheumatology and Immunology, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui, China

Received:2018-09-16 Revised:2018-10-19 Online:2018-12-26 Published:2018-12-27

摘要/Abstract

摘要：

目的: 研究羟氯喹(hydroxychloroquine,HCQ) 给药剂量、疗程、合并用药(激素、环磷酰胺、吗替麦考酚酯和甲氨蝶呤)及患者疾病类型、年龄、性别等因素对HCQ血药浓度的影响。方法: 病例来自安徽医科大学第一附属医院风湿免疫科2017年7月至2018年6月长期(>6个月)服用HCQ的自身免疫性疾病患者，谷浓度标本为当天患者服药前抽取静脉血获得。采用高效液相色谱法(high performance liquid chromatography, HPLC)监测患者全血中HCQ的血药浓度。采用SPSS 16.0统计分析软件对相关数据进行统计学处理。结果: HCQ给药剂量为0.4 g/d时血药浓度较高；年龄超过50岁的病人及HCQ治疗疗程超过10年的患者，HCQ血药浓度明显高于其他各组，结果存在统计学差异(P<0.05)，其他因素 (疾病类型、患者性别及合并用药) 对HCQ血药浓度无显著影响。且随着HCQ血药浓度增加，不良反应发生率增高。结论: HCQ的血药浓度主要受患者年龄、给药剂量及疗程的影响，0.4 g/d给药，HCQ血药浓度较高；高龄及长期用药患者，适当降低HCQ剂量即可达到相同治疗效果；可通过监测HCQ血药浓度调整给药剂量，以减轻不良反应。

关键词: 羟氯喹, 血药浓度, 自身免疫性疾病, 影响因素分析

Abstract:

AIM: To explore the factors that influence the blood concentration of hydroxychloroquine (HCQ) including dosage, treatment course, and combination of the drug (hormone, cyclophosphamide, mycophenolate mofetil and methotrexate), as well as the disease type, age and gender of the patients. METHODS: During July 2017 to June 2018, blood samples were collected from autoimmune diseases patients who had been treated with HCQ for more than 6 months in department of rheumatology and immunology of our hospital. The blood concentration of HCQ was monitored by high performance liquid chromatography (HPLC). Statistical analyses were performed by SPSS 16.0. RESULTS: The blood concentration of HCQ was relatively high in patients treated with 0.4 g HCQ per day. Patients that over 50 years old and/or have been treated with HCQ for more than 10 years presented significant higher HCQ blood concentration (P<0.05). Other factors including disease type, gender and drug combination didn't obviously affect the concentration of HCQ. Moreover, we found that the incidence of adverse drug reactions was increased along with the increase of HCQ blood concentration. CONCLUSION: The blood concentration of HCQ is mainly affected by the dosage, the age of the patients, and the course of HCQ treatment. The equivalent therapeutic effect can be achieved with lower HCQ dosage in elderly and long-term treatment patients. Adjustment the dosage according to the blood HCQ concentration monitoring could decrease the incidence of adverse drug reactions.

Key words: hydroxychloroquine, blood concentration, autoimmune diseases, influence factors analysis

中图分类号:

刘婷婷，余威，杨春兰，帅宗文，高贝贝，夏泉. 羟氯喹治疗自身免疫性疾病血药浓度影响因素分析[J]. 中国临床药理学与治疗学, 2018, 23(12): 1359-1363.

LIU Tingting, YU Wei, YANG Chunlan, SHUAI Zongwen, GAO Beibei, XIA Quan. Blood concentration monitoring of hydroxychloroquine in patients with autoimmune diseases[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1359-1363.

参考文献

［1］李小心，徐亮. 类风湿性关节炎缓解后的维持治疗研究进展［J］. 中国临床药理学与治疗学，2014,19(1): 116-120.
［2］Shippey EA, Wagler VD, Collamer AN. Hydroxychloroquine: An old drug with new relevance［J］. Cleve Clin J Med,2018,85(6):459-467.
［3］国家风湿病数据中心及CSTAR专家共识组. 羟氯喹治疗风湿性疾病专家共识［J］. 中华风湿病学杂志，2014,18(3) :148-150.
［4］Monzavi SM, Alirezaei A, Shariati-Sarabi Z, et al. Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers［J］. Inflammopharmacol,2018 Jul 10. ［Epub ahead of print］
［5］罗雪梅，司慧敏，姚瑶，等. 全血及血清中羟氯喹HPLC测定方法的建立及其应用［J］. 药学与临床研究，2015,(6): 562-564.
［6］Qu Y, Noe G, Breaud AR, et al. Development and validation of a clinical HPLC method for the quantification of hydroxychloroquine and its metabolites in whole blood［J］. Future Sci OA, 2015,1(3): FSO26.
［7］Espinosa E,Valitutti S,Laroche M,et al.Hydroxychloroquine as a novel therapeutic approach in mast cell activation diseases［J］.Clin Immunol,2018,194:75-79.
［8］Tanaka E,Taniguchi A,Urano W,et al.Pharmacogenetics of disease-modifying anti-rheumatic drugs［J］.Best Pract Res Clin Rheumatol,2004,18(2):233-247.
［9］Ma H, Zhao L, Jiang Z, et al. Dynamic changes in the numbers of different subsets of peripheral blood NK cells in patients with systemic lupus erythematosus following classic therapy ［J］. Clin Rheumatol,2014,33(11): 1603-1610.
［10］解方，赵梓纲，赵华. 吡美莫司乳膏联合羟氯喹片治疗扁平苔癣的疗效及安全性观察［J］. 中国药物应用与监测，2012,9(2): 70-72.
［11］Tétu P, Hamelin A, Lebrun-Vignes B, et al. Prevalence of hydroxychloroquine-induced side-effects in dermatology patients: A retrospective survey of 102 patients ［J］. Ann Dermatol Venereol, 2018,145(6/7): 395-404.
［12］Moya FB,Pineda Calindo LF,Carcia de la Pena M.Impact of chronic glucocorticoid treatment on cardiovascular risk profile in patients with systemic lupus erythematosus［J］.J Clin Rheumatol,2016,22(1): 8-12.
［13］沈斌，张斌，徐亮，等. 风湿免疫科门诊超说明书用药调查与分析［J］. 中国临床药理学与治疗学，2017,22(3): 337-341.
［14］Bruni C, Praino E, Guiducci S, et al. Hydroxychloroquine and joint involvement in systemic sclerosis: Preliminary beneficial results from a retrospective case-control series of an EUSTAR center［J］. Joint Bone Spine,2017,84(6): 747-748.
［15］徐冬，吕晓伟，崔鹏，等. 艾拉莫德与羟氯喹治疗干燥综合征患者疗效及安全性比较［J］. 疑难病杂志，2017,16(9): 915-918.
［16］Lee JY, Vinayagamoorthy N, Han K, et al. Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus［J］. Arthritis Rheumatol,2016,68(1): 184-190.
［17］韩龙，孙桂芳. 滋阴润燥生津汤联合硫酸羟化氯喹治疗干燥综合征临床研究［J］. 中医药信息，2014,(3): 60-63.
［18］中华医学会风湿免疫分会.类风湿关节炎诊断及治疗指南［J］.中华内科杂志，2018,57(4):242-251.
［19］中华医学会风湿免疫分会. 系统性红斑狼疮诊断及治疗指南［J］. 中华风湿病学杂志，2010,14(4): 265-270.
［20］Jallouli M, Saadoun D, Eymard B, et al. The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature［J］. J Neurol,2012,259(7):1290-1297.

[1]	余巧玲, 翟葳葳, 刘平, 邱博, 吴惠珍. 利伐沙班血药浓度监测的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 809-817.
[2]	柳彤, 徐佳明, 王金伙, 尹磊, 陈永权, 郭建荣. 急性等容血液稀释自体血体外隔离期间血浆中麻醉药物浓度变化及回输后对麻醉效应的影响[J]. 中国临床药理学与治疗学, 2023, 28(4): 413-418.
[3]	杜文鹏, 敖检根, 陶祎, 吴观胜, 何佳珂. 自身免疫疾病患者他克莫司稳态血药浓度影响因素的研究[J]. 中国临床药理学与治疗学, 2022, 27(6): 645-651.
[4]	胡殷, 杨丹丹, 徐毅超, 邵蓉, 阮邹荣, 江波, 陈金亮, 楼洪刚. 人工神经网络模型在坎地沙坦酯片生物等效性研究中的应用[J]. 中国临床药理学与治疗学, 2022, 27(1): 63-69.
[5]	符祥俊, 黄莉, 郭丽, 林良沫. 万古霉素AUC/MIC在多重耐药革兰阳性菌致重症感染中的应用分析[J]. 中国临床药理学与治疗学, 2021, 26(7): 775-781.
[6]	尹磊, 徐佳明, 吴敬医, 段立双, 卫含伟, 金孝岠, 郭建荣. 急性等容血液稀释自体血回输对老年骨科手术患者脑电双谱指数与肌松效应的影响[J]. 中国临床药理学与治疗学, 2021, 26(10): 1153-1158.
[7]	林荣芳, 郑玮玮, 刘亦伟, 林翠鸿, 王长连, 黄品芳. 克罗恩病患者英夫利西单抗相关基因多态性与血药浓度及疗效关联性研究[J]. 中国临床药理学与治疗学, 2020, 25(9): 1000-1006.
[8]	郭明星, 郭恒, 沈素, 孙丽莹, 崔向丽. 肝功能不全患者伏立康唑血药浓度监测回顾性研究[J]. 中国临床药理学与治疗学, 2020, 25(7): 757-763.
[9]	孙青, 孙建芳, 李力, 常会超, 周权. 五酯胶囊对大鼠体内辛伐他汀及其代谢物辛伐他汀酸药代动力学影响[J]. 中国临床药理学与治疗学, 2020, 25(11): 1242-1249.
[10]	李力，李贺，刘杏娥，魏楠. LC-MS/MS法测定肿瘤患者血浆中阿帕替尼浓度及其临床应用[J]. 中国临床药理学与治疗学, 2018, 23(7): 790-795.
[11]	陈曜曜，史道华，刘光华，牛培广，刘柏晨. OCT2、MDR1基因多态性与婴幼儿万古霉素血药浓度及临床疗效的相关性研究[J]. 中国临床药理学与治疗学, 2018, 23(2): 154-158.
[12]	成舒乔，陈尧，黄卫华，谢海棠，肖坚. 丙戊酸钠缓释片在健康人体内的药动学研究[J]. 中国临床药理学与治疗学, 2016, 21(5): 533-537.
[13]	南峰，陈枳潓，向瑾，余勤，秦永平，梁茂植. 正负离子切换同时测定布洛芬、伪麻黄碱、氯苯那敏血浆浓度的HPLC-MS/MS法[J]. 中国临床药理学与治疗学, 2016, 21(2): 173-177.
[14]	李贺，陈国耘，沈琦，黄越，朱逢佳，刘炜，李力. LC-MS/MS法测定人血浆中西格列汀浓度及其药物动力学研究[J]. 中国临床药理学与治疗学, 2016, 21(10): 1144-1148.
[15]	王梓坤，陈舒晴，周颖，赵侠，许俊羽，崔一民. 合并用药对有无肾损伤患者地高辛血药浓度影响因素分析[J]. 中国临床药理学与治疗学, 2016, 21(1): 71-76.

羟氯喹治疗自身免疫性疾病血药浓度影响因素分析

Blood concentration monitoring of hydroxychloroquine in patients with autoimmune diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价